Bruce E. Sands, MD, FACG

Icahn School of Medicine at Mount Sinai

Poster(s):

• P4350 - Efficacy of Guselkumab vs Placebo In Crohn’s Disease Based on Prior Response/Exposure to Biologic Therapy: Results of the GALAXI 2 and 3 Phase 3 Studies
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4351 - Efficacy and Safety of Long-Term Mirikizumab Treatment in Patients With Moderate to Severe Crohn’s Disease
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4352 - Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4353 - Impact of Prior Biologic Exposure on the Durability of Ozanimod Over 5 Years of Continuous Treatment in Patients With Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension Study
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4354 - Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4355 - Long-Term Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment: Results From the LUCENT-3 Open-Label Extension Study
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4356 - Efficacy and Safety Profile of Etrasimod Was Not Impacted by Baseline Disease Activity: A Post Hoc Analysis of the ELEVATE UC Program
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4357 - Early Symptomatic Improvement With Mirikizumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 VIVID-1 Study
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4358 - Disease Characteristics Associated With Bowel Urgency in Crohn’s Disease: Results From the Phase 3 VIVID-1 Trial
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4359 - Long-Term Efficacy and Safety of Intravenous (IV) Tulisokibart in Patients With Ulcerative Colitis (UC): Results From the Open-Label Extension (OLE) Period of the Phase 2 ARTEMIS-UC Study
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET